FDA Calls on Health Experts to Advise on Testosterone Products Amid Growing Reports of Adverse Reactions and Injury Lawsuits, Rottenstein Law Group LLP Reports
In light of the growing concern about the dangers of prescription testosterone products, the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee for September 17.* The published agenda states: “The committees will discuss the appropriate indicated population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with this use.” The Rottenstein Law Group, a national...
View full press release